EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan

Yukio Maruyama iD, Keitaro Yokoyama, Chieko Higuchi, Tsutomu Sanaka, Yoshihide Tanaka, Ken Sakai, Yoshihiko Kanno, Munekazu Ryuzaki, Tsutomu Sakurada iD, Tatsuo Hosoya, Masaaki Nakayama, EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group

Therapeutic Apheresis and Dialysis · 2023-08 · 27 (4) · 735-741

DOI: 10.1111/1744-9987.13981 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 22.03.2023. Verfasst von Yukio Maruyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hematinics, Peritoneal Dialysis, Kidney Failure, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: the Kidney Foundation, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inadequate dialysis and fluid overload are corrected after starting combined therapy with peritoneal dialysis (PD) and hemodialysis (HD). However, the effects on anemia management has not been elucidated.

Methods

We conducted a prospective, multicenter, observational cohort study of 40 PD patients (age, 60 ± 10 years; male, 88%; median PD duration, 28 months) starting combined therapy and investigated changes in several clinical parameters, including erythropoiesis‐stimulating agent (ESA) resistance index (ERI).

Results

ERI decreased significantly during 6 months after switching to combined therapy (from 11.8 [IQR 8.0–20.4] units/week/kg/(g/dL) to 7.8 [IQR 3.9–18.6] units/week/kg/(g/dL), p = 0.047). Body weight, urinary volume, serum creatinine and the dialysate‐to‐plasma creatinine ratio (D/P Cr) decreased, whereas hemoglobin and serum albumin increased. In subgroup analysis, the changes in ERI were not affected by cause for starting combined therapy, PD holiday and D/P Cr.

Conclusion

Although detailed mechanism was unclear, ESA responsiveness improved after switching from PD alone to combined therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematinicsPeritoneal DialysisKidney Failure, ChronicHumansMaleMiddle AgedAgedErythropoiesisProspective StudiesJapanRenal DialysisHemoglobins

Stichwörter der Autor:innen

ESA resistance index (ERI)dialysate-to-plasma ratio of creatinine (D/P Cr)erythropoiesis-stimulating agent (ESA)residual kidney function (RKF)β2 microglobulin

Substanzen

HematinicsHemoglobins

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Internal Medicine, Tokyo, Japan.
  • Shibagaki Dialysis Clinic, Tokyo, Japan.
  • Center of CKD and Lifestyle Related Diseases, Edogawa Hospital, Ichikawa, Japan.
  • Department of Nephrology, Toho University School of Medicine, Tokyo, Japan.
  • Department of Nephrology, Tokyo Medical University, Tokyo, Japan.
  • Division of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

ORCID-Profile: Yukio Maruyama, Tsutomu Sakurada

Förderung

  • the Kidney Foundation, Japan

Zitieren

APA

Maruyama, Y., Yokoyama, K., Higuchi, C., Sanaka, T., Tanaka, Y., Sakai, K., Kanno, Y., Ryuzaki, M., Sakurada, T., Hosoya, T., Nakayama, M., & EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group (2023). Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis, 27(4), 735-741. https://doi.org/10.1111/1744-9987.13981

Vancouver

Maruyama Y, Yokoyama K, Higuchi C, Sanaka T, Tanaka Y, Sakai K, et al. Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis. 2023;27(4):735-741. doi:10.1111/1744-9987.13981

BibTeX
@article{Maruyama2023,
  author = {Maruyama, Yukio and Yokoyama, Keitaro and Higuchi, Chieko and Sanaka, Tsutomu and Tanaka, Yoshihide and Sakai, Ken and Kanno, Yoshihiko and Ryuzaki, Munekazu and Sakurada, Tsutomu and Hosoya, Tatsuo and Nakayama, Masaaki and EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group, EARTH (Evaluation of the Adequacy of Renal replacement THerapy) study group},
  title = {Changes in erythropoiesis‐stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2023},
  volume = {27},
  number = {4},
  pages = {735--741},
  doi = {10.1111/1744-9987.13981}
}
Kostenlos starten →